Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus

ObjectiveImmune checkpoint inhibitors(ICIs) have improved survival and are increasingly used for cancer. However, ICIs use may be limited by immune-related adverse events (irAEs), such as ICI-induced diabetes mellitus(ICI-DM). The objective of the present study was to characterize ICI-DM patients an...

Full description

Bibliographic Details
Main Authors:	Min Shen, Doudou Chen, Ruiling Zhao, Xuqin Zheng, Yong Gu, Tao Yang, Yun Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Endocrinology
Subjects:	immune-related adverse events immune checkpoint inhibitors toxicity guideline adherence diabetes mellitus proposal
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1213225/full

Similar Items

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
by: Arezou Teimouri, et al.
Published: (2022-04-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

Imaging assessment of toxicity related to immune checkpoint inhibitors
by: Antonia M. Berz, et al.
Published: (2023-02-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)

Hepatotoxicity induced by immune checkpoint inhibitors
by: Flaviu Muresan, et al.
Published: (2024-10-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report
by: Marie Okubo, et al.
Published: (2023-01-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Checkpoint inhibitor induced esophagitis with documented resolution on infliximab
by: Frank W. Chen, et al.
Published: (2020-12-01)

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
by: Johnny Chahine, MD, et al.
Published: (2020-02-01)

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
by: Fan Yang, et al.
Published: (2023-01-01)

Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
by: Marta Rocha, et al.
Published: (2018-12-01)

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
by: J. Randall Patrinely, et al.
Published: (2021-01-01)

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
by: David O’Reilly, et al.
Published: (2024-07-01)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
by: Katarina Hradska, et al.
Published: (2021-08-01)

Toxicity in the era of immune checkpoint inhibitor therapy
by: Synat Keam, et al.
Published: (2024-08-01)

Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials
by: Akanksha Srivastava, et al.
Published: (2024-02-01)

Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors
by: Nicholas Gulati, et al.
Published: (2020-11-01)

Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
by: Jingxin Ma, et al.
Published: (2023-06-01)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
by: Xiaowei Liu, et al.
Published: (2020-03-01)

Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
by: Anam A. Mazharuddin, et al.
Published: (2022-11-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Hepatobiliary complications of immune checkpoint inhibitors in cancer
by: Donna Zhuang, et al.
Published: (2024-07-01)

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0
by: Rodrigo Ramella Munhoz, et al.
Published: (2022-10-01)

Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors
by: Ru Chen, et al.
Published: (2021-12-01)

Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors
by: Hidefumi Inaba, et al.
Published: (2022-02-01)

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
by: Robin Hilder, et al.
Published: (2023-10-01)

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study
by: Yizhang Hu, et al.
Published: (2022-09-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis
by: Lin Zhou, et al.
Published: (2024-11-01)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
by: Hanna Karhapää, et al.
Published: (2022-02-01)

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
by: Parneet K. Cheema, et al.
Published: (2024-10-01)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
by: Keita Saito, et al.
Published: (2022-04-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
by: Liyan Zhang, et al.
Published: (2021-01-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)